Half-Year 2022 Financial and Clinical Trials Update

Hemlibra Global sales CHFbn CER growth +30% Regional sales CER growth US +26% 2.0 Europe +30% 1.6 1.2 0.8 0.4 0.0 HY 19 HY 20 HY 21 HY 22 HY 2022 sales of CHF 1,826m • US: Continued share gains in non-inhibitor patients • Japan +19% International +89% EU: Continued share gains in non-inhibitor severe patients with market shares > 50% in France, UK and GER, Italy, Spain >20% • Japan: Strong uptake in non-inhibitor patients International: Accelerating momentum driven by becoming new SoC in key markets CER-Constant Exchange Rates Roche 172

View entire presentation